ZBIO · Zenas BioPharma
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $24.00
Note written ·
Price against the kill line
16.7% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $24.00, on record since 10 November 2026; only a weekly close settles it. The shares are down 8.2% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $24.00, which would take the shares under the 200-day moving average and undo the summer rebound. A SunStone primary-endpoint miss in the overall population, or a change to the 27 May 2027 FDA action date, would also show the case failing.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 10.0
- Operating margin (%)
- −1034.1
- Free cash flow, four quarters ($M)
- −243
- Net cash, cash less debt ($M)
- 348
- Free-cash-flow yield (%)
- −12.8
All filed numbers
What Zenas BioPharma reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 10.0 | — | −1034.1 |
| first filed | 1.0 | — | −10765.9 |
| first filed | 0.0 | −100.0 | — |
| first filed | 0.0 | — | — |
| first filed | 0.0 | — | — |
| Pre-tax income ($M) | −109 |
| Net income ($M) four quarters: −542 | −109 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +56.9 |
| Operating cash flow ($M) | −243 |
| Capital spending ($M) | 0.0 |
| Free cash flow ($M) | −243 |
| Cash and short-term investments ($M) | 647 |
| Debt ($M) notes plus secured debt | 299 |
| Net cash, cash less debt ($M) | 348 |
| Deferred revenue ($M) | 2.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 212 |
| Market value ($M) | 1,900 |
| Enterprise value, market value plus net debt ($M) | 1,552 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 8.9 |
| Free-cash-flow yield (%) | −12.8 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 18.5% of shares outstanding sold short, 18.8 days of average trading to cover, +5.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $11.4M | $0 |
The thesis
Zenas BioPharma is modestly more likely than not to beat the S&P 500 over the next three months, and the SunStone Phase 2 lupus result for obexelimab, guided for the fourth quarter of 2026, settles it. A primary-endpoint success would take the drug beyond immunoglobulin G4-related disease (IgG4-RD), where the Food and Drug Administration (FDA) set a 27 May 2027 target action date.
The shares closed at $27.64 on 12 November 2026, down from $28.70 on 11 November. They are 6.3% lower than three months earlier on adjusted closes. The close sits just under the 50-day average of $28.68 and above the 200-day average of $25.31.
Company news since the 5 November third-quarter report is limited to a 9 November announcement that Zenas will present at the Jefferies London Global Healthcare Conference. The SunStone readout has no fixed date, so it can arrive without notice. The IgG4-RD approval path has been known since the FDA accepted the application in August 2026, so the quarter's price action depends on the lupus data.
Bullish and bearish views on Zenas BioPharma, Inc.
The bull case on Zenas BioPharma, Inc. (ZBIO), in brief: the FDA date and INDIGO result stand. The bear case: the quarterly loss widened sharply.
Bull case
- The FDA date and INDIGO result stand. Zenas reported on 2 June 2026 that its INDIGO trial cut IgG4-RD flare risk by 56% versus placebo (hazard ratio 0.44) and met all four key secondary endpoints. The 5 November release repeats the 27 May 2027 action date and says the European Medicines Agency validated the marketing application.
- Lupus timing held on 5 November. The company's release expects SunStone topline results, including a biomarker subset, in the fourth quarter of 2026. A positive primary endpoint would add a second indication for the same drug.
- Cash covers the guided readouts. Cash, cash equivalents and investments were $647.1 million at 30 September 2026. On 5 November, Zenas kept its guidance for funding through at least the second quarter of 2029.
- ZB021 offers a second readout this quarter. Zenas expects Phase 1 data for its oral interleukin-17AA/AF inhibitor in the fourth quarter of 2026, per the 5 November release. Proof-of-concept data are guided for 2027.
Bear case
- The quarterly loss widened sharply. Zenas reported a third-quarter 2026 net loss of $108.9 million, against $51.5 million a year earlier. The loss of $(1.65) per share missed the $(1.33) estimate cited in a 5 November earnings headline.
- Revenue remains milestone income. The $10.0 million of third-quarter revenue came from a Bristol-Myers Squibb development milestone, according to the 5 November release. Zenas has no approved product.
- Share supply keeps growing. The third-quarter 10-Q shows 1,818,181 shares sold through the at-the-market program for about $48.5 million net, plus 2,000,000 shares issued to InnoCare as a milestone payment. Shares outstanding were 67,817,793 on 30 October 2026, and resale of up to 7,000,000 InnoCare shares has been registered since 11 September.
- One readout carries the expansion case. A SunStone miss would leave the valuation resting on a single rare-disease indication. A win confined to the biomarker subset would leave the broad lupus market unproven.
- Funding depends on approval. The runway guidance through the second quarter of 2029 assumes $75 million from Royalty Pharma and a $75 million Pharmakon debt draw, both tied to FDA approval.
Price setup
The shares closed at $27.64 on 12 November 2026. They closed at $25.93 on 5 November, $28.26 on 6 November and $28.70 on 11 November. The three-month reference close was $29.51 on 14 August.
The 200-day average of $25.31 sits below the last close and the 50-day average of $28.68 sits just above it. The quoted 52-week high is $44.60, reached intraday on 24 December 2025, and the last close is 38.0% below it. The 52-week closing low was $15.20 on 6 January 2026.
Share supply adds to the binary risk. At-the-market sales, the InnoCare milestone shares and the registered InnoCare resale capacity all add stock that could be sold into strength.
Catalysts ahead
- ~31 December 2026 (est.): SunStone Phase 2 lupus topline results, guided to the fourth quarter of 2026 with no specific date. The primary endpoint decides whether obexelimab's market widens beyond IgG4-RD.
- ~31 December 2026 (est.): ZB021 Phase 1 data, guided to the fourth quarter of 2026 with no specific date. Pharmacokinetic and safety results show whether the oral IL-17AA/AF program can move to its proof-of-concept trial, with data guided for 2027.
- 27 May 2027: FDA target action date for obexelimab in IgG4-RD. The decision determines the first commercial product and whether the approval-linked funding in the runway guidance becomes available.
What would change the view
A weekly close below $24.00, which would take the shares under the 200-day moving average and undo the summer rebound. A SunStone primary-endpoint miss in the overall population, or a change to the 27 May 2027 FDA action date, would also show the case failing.
The risks this note tracks, each with what would confirm it:
- SunStone fails its Phase 2 lupus primary endpoint or succeeds only in the biomarker subset. Confirmed by: the topline release reports a primary-endpoint miss in the overall population, or the readout slips past the fourth quarter of 2026.
- Share issuance and registered InnoCare resale capacity weigh on the shares. Confirmed by: a later 10-Q shows further at-the-market sales, or an ownership filing shows InnoCare disposals.
- Runway proves shorter than guided if FDA approval is delayed or denied. Confirmed by: an FDA rejection or date change, or later guidance moving funding earlier than the second quarter of 2029.
- Amgen's Uplizna limits obexelimab's commercial uptake in IgG4-RD. Confirmed by: an approved obexelimab label or early launch results that trail Uplizna on efficacy or dosing convenience.
What it trades with
Zenas trades as a single-event biotech. The SunStone readout will move the shares far more than the broad market or biotech indices do. Peers in B-cell autoimmune therapy, notably Amgen's Uplizna in IgG4-RD, shape the commercial comparison, while lupus readouts from other developers can shift sentiment toward the indication. Relative performance over the next quarter depends mostly on the trial result.
The evidence, claim by claim (6)
- Third-quarter 2026 net loss was $108.9 million, or $(1.65) per share, versus $51.5 million and $(1.22) a year earlier; revenue was $10.0 million from a Bristol-Myers Squibb development milestone. Zenas third-quarter 2026 results release and Form 8-K exhibit · as of
- Cash, cash equivalents and investments totaled $647.1 million at 30 September 2026; runway is guided through at least the second quarter of 2029, assuming $75 million from Royalty Pharma and a $75 million Pharmakon draw, both tied to approval. Zenas third-quarter 2026 results release · as of
- Zenas expects SunStone Phase 2 lupus topline results, including a biomarker subset, and ZB021 Phase 1 data in the fourth quarter of 2026. Zenas third-quarter 2026 results release · as of
- In the third quarter of 2026 Zenas issued 1,818,181 shares under its at-the-market program for about $48.5 million net and 2,000,000 shares to InnoCare as a milestone payment; 67,817,793 shares were outstanding on 30 October 2026. Zenas Form 10-Q for the quarter ended 30 September 2026 · as of
- INDIGO reduced IgG4-RD flare risk by 56% versus placebo (hazard ratio 0.44) and met all four key secondary endpoints. Zenas INDIGO results release · as of
- The FDA accepted the obexelimab IgG4-RD application in August 2026 with a 27 May 2027 target action date, and the European Medicines Agency validated the marketing application. Zenas third-quarter 2026 results release · as of
Sources
- Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update · globenewswire.com ·
- Zenas BioPharma, Inc. - Form 8-K - FY2026 · sec.gov ·
- Zenas BioPharma, Inc. - Form 10-Q - FY2026 · sec.gov
Related · shared themes
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
SLS
SELLAS Life Sciences Group
SELLAS Life Sciences is more likely to lag the S&P 500 over three months: its value rests on one Phase 3 leukemia trial, REGAL, whose…
CORT
Corcept Therapeutics
Corcept Therapeutics' Lifyorli launch is compounding ($91.4 million in Q3 2026, up from $47.6 million in Q2), yet the shares sit near their…
See also · stocks to watch